Ellagic acid reduces hepatic lipid contents through regulation of SIRT1 and AMPK in old rats.

IF 2.5 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Archives of Physiology and Biochemistry Pub Date : 2024-12-01 Epub Date: 2023-10-10 DOI:10.1080/13813455.2023.2262165

Mahdis Rahimi Naiini, Beydolah Shahouzehi, Mohammad Khaksari, Shahrzad Azizi, Niloufar Naghibi, Mahdieh Nazari-Robati

{"title":"Ellagic acid reduces hepatic lipid contents through regulation of SIRT1 and AMPK in old rats.","authors":"Mahdis Rahimi Naiini, Beydolah Shahouzehi, Mohammad Khaksari, Shahrzad Azizi, Niloufar Naghibi, Mahdieh Nazari-Robati","doi":"10.1080/13813455.2023.2262165","DOIUrl":null,"url":null,"abstract":"Objective: Ellagic acid is used in traditional medicine for the treatment of lipid disorders. In this study, the effects of ellagic acid on key regulators of lipid metabolism, and histopathological alterations in aged liver were examined.Methods: A total of 21 male Wistar rats were divided into three groups, including young control, old control, and old ellagic acid. After one month of treatment with ellagic acid, the expression levels of hepatic SIRT1, AMPK, SREBP-1c, PPAR-α, and phosphorylated AMPK (p-AMPK) were evaluated. The levels of several serum biochemical factors, and hepatic triglyceride, and cholesterol contents were assessed.Results: Ellagic acid elevated the levels of SIRT1, p-AMPK, and PPAR-α and reduced SREBP-1c level in the liver of old rats. It decreased triglyceride and cholesterol contents in the aged liver and improved histopathological changes.Conclusions: The results demonstrated that ellagic acid can exert protective effects against hepatic lipid metabolism disorders induced by ageing.","PeriodicalId":8331,"journal":{"name":"Archives of Physiology and Biochemistry","volume":" ","pages":"686-693"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Physiology and Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13813455.2023.2262165","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Ellagic acid is used in traditional medicine for the treatment of lipid disorders. In this study, the effects of ellagic acid on key regulators of lipid metabolism, and histopathological alterations in aged liver were examined.

Methods: A total of 21 male Wistar rats were divided into three groups, including young control, old control, and old ellagic acid. After one month of treatment with ellagic acid, the expression levels of hepatic SIRT1, AMPK, SREBP-1c, PPAR-α, and phosphorylated AMPK (p-AMPK) were evaluated. The levels of several serum biochemical factors, and hepatic triglyceride, and cholesterol contents were assessed.

Results: Ellagic acid elevated the levels of SIRT1, p-AMPK, and PPAR-α and reduced SREBP-1c level in the liver of old rats. It decreased triglyceride and cholesterol contents in the aged liver and improved histopathological changes.

Conclusions: The results demonstrated that ellagic acid can exert protective effects against hepatic lipid metabolism disorders induced by ageing.

查看原文本刊更多论文

Ellagic酸通过调节SIRT1和AMPK降低老年大鼠肝脏脂质含量。

前言：目的：艾拉吉酸在传统医学中用于治疗脂质紊乱。在本研究中，研究了鞣花酸对衰老肝脏脂质代谢关键调节因子的影响以及组织病理学变化。方法：将21只雄性Wistar大鼠分为三组，分别为青年对照组、老年对照组和老年鞣花酸组。鞣花酸治疗一个月后，评估肝脏SIRT1、AMPK、SREBP-1c、PPAR-α和磷酸化AMPK（p-AMPK）的表达水平。评估了几种血清生化因子、肝甘油三酯和胆固醇含量的水平。结果：Ellagic acid使老年大鼠肝脏SIRT1、p-AMPK和PPAR-α水平升高，SREBP-1c水平降低。它降低了老年肝脏中甘油三酯和胆固醇的含量，改善了组织病理学变化。结论：鞣花酸对衰老引起的肝脏脂质代谢紊乱具有保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archives of Physiology and Biochemistry ENDOCRINOLOGY & METABOLISM-PHYSIOLOGY

CiteScore

6.90

自引率

3.30%

发文量

期刊介绍： Archives of Physiology and Biochemistry: The Journal of Metabolic Diseases is an international peer-reviewed journal which has been relaunched to meet the increasing demand for integrated publication on molecular, biochemical and cellular aspects of metabolic diseases, as well as clinical and therapeutic strategies for their treatment. It publishes full-length original articles, rapid papers, reviews and mini-reviews on selected topics. It is the overall goal of the journal to disseminate novel approaches to an improved understanding of major metabolic disorders. The scope encompasses all topics related to the molecular and cellular pathophysiology of metabolic diseases like obesity, type 2 diabetes and the metabolic syndrome, and their associated complications. Clinical studies are considered as an integral part of the Journal and should be related to one of the following topics: -Dysregulation of hormone receptors and signal transduction -Contribution of gene variants and gene regulatory processes -Impairment of intermediary metabolism at the cellular level -Secretion and metabolism of peptides and other factors that mediate cellular crosstalk -Therapeutic strategies for managing metabolic diseases Special issues dedicated to topics in the field will be published regularly.